LT3523283T - Ppar agonistų junginių kristalinės ir druskos formos - Google Patents
Ppar agonistų junginių kristalinės ir druskos formosInfo
- Publication number
- LT3523283T LT3523283T LTEPPCT/US2017/055403T LT17787774T LT3523283T LT 3523283 T LT3523283 T LT 3523283T LT 17787774 T LT17787774 T LT 17787774T LT 3523283 T LT3523283 T LT 3523283T
- Authority
- LT
- Lithuania
- Prior art keywords
- crystalline
- salt forms
- agonist compounds
- ppar agonist
- ppar
- Prior art date
Links
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 150000003839 salts Chemical group 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404474P | 2016-10-05 | 2016-10-05 | |
| PCT/US2017/055403 WO2018067860A1 (en) | 2016-10-05 | 2017-10-05 | Crystalline and salt forms of ppar agonist compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3523283T true LT3523283T (lt) | 2021-07-12 |
Family
ID=60153508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/US2017/055403T LT3523283T (lt) | 2016-10-05 | 2017-10-05 | Ppar agonistų junginių kristalinės ir druskos formos |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US10927094B2 (lt) |
| EP (1) | EP3523283B1 (lt) |
| JP (1) | JP7017563B2 (lt) |
| KR (1) | KR20190057129A (lt) |
| CN (1) | CN109843857B (lt) |
| AU (1) | AU2017340763B2 (lt) |
| CA (1) | CA3036587A1 (lt) |
| CO (1) | CO2019003162A2 (lt) |
| CY (1) | CY1124655T1 (lt) |
| DK (1) | DK3523283T3 (lt) |
| ES (1) | ES2887008T3 (lt) |
| HR (1) | HRP20211341T1 (lt) |
| HU (1) | HUE055678T2 (lt) |
| IL (1) | IL265730B (lt) |
| JO (1) | JOP20190039B1 (lt) |
| LT (1) | LT3523283T (lt) |
| MA (1) | MA46460A (lt) |
| MX (1) | MX385973B (lt) |
| MY (1) | MY202008A (lt) |
| PH (1) | PH12019500727A1 (lt) |
| PL (1) | PL3523283T3 (lt) |
| PT (1) | PT3523283T (lt) |
| RS (1) | RS62245B1 (lt) |
| RU (1) | RU2759724C2 (lt) |
| SG (1) | SG11201901995TA (lt) |
| SI (1) | SI3523283T1 (lt) |
| TW (1) | TWI769182B (lt) |
| UA (1) | UA124770C2 (lt) |
| WO (1) | WO2018067860A1 (lt) |
| ZA (1) | ZA201901744B (lt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101321742B (zh) | 2005-05-26 | 2012-08-29 | 神经元系统公司 | 用于治疗视网膜疾病的组合物和方法 |
| US9814701B2 (en) | 2009-12-11 | 2017-11-14 | Aldeyra Therapeutics, Inc. | Compositions and methods for the treatment of macular degeneration |
| CN111135171B (zh) | 2013-01-23 | 2023-09-08 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| CN118724806A (zh) | 2015-08-21 | 2024-10-01 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
| CN108349904B (zh) * | 2015-10-07 | 2021-08-31 | 米托布里奇公司 | Ppar激动剂、化合物、药物组合物及其使用方法 |
| SG11201901995TA (en) | 2016-10-05 | 2019-04-29 | Mitobridge Inc | Crystalline and salt forms of ppar agonist compounds |
| JP7311162B2 (ja) | 2017-10-10 | 2023-07-19 | アルデイラ セラピューティクス， インコーポレイテッド | 炎症性障害の処置 |
| CN112714762A (zh) * | 2018-08-06 | 2021-04-27 | 奥尔德拉医疗公司 | 多晶型化合物及其用途 |
| EP3871667A4 (en) | 2018-10-23 | 2022-08-17 | Japan Science and Technology Agency | PPAR DELTA ACTIVATOR |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| CN113784954A (zh) | 2019-05-02 | 2021-12-10 | 奥尔德拉医疗公司 | 多晶型化合物和其用途 |
| JP2023526016A (ja) | 2020-05-13 | 2023-06-20 | アルデイラ セラピューティクス， インコーポレイテッド | 医薬製剤およびその使用 |
| WO2022256540A1 (en) | 2021-06-02 | 2022-12-08 | Astellas Pharma Inc. | Methods of use of ppar agonist compounds and pharmaceutical compositions thereof |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
| WO2025207099A1 (en) * | 2024-03-28 | 2025-10-02 | Astellas Pharma Inc. | Ppar-delta inhibitors for preventing post-operative atrial fibrillation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1583746A1 (en) | 2003-01-06 | 2005-10-12 | Eli Lilly And Company | A pyrazole derivative as ppar modulator |
| EP1671633A1 (en) | 2004-12-17 | 2006-06-21 | Sanofi-Aventis Deutschland GmbH | Use of PPAR agonists for the treatment of congestive heart failure |
| JP2008528700A (ja) | 2005-02-03 | 2008-07-31 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｐｐａｒモジュレーターとしての化合物および組成物 |
| CN101296892A (zh) * | 2005-09-07 | 2008-10-29 | 普莱希科公司 | Ppar活性化合物 |
| DE102006023336A1 (de) * | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
| FR2940289B1 (fr) | 2008-12-23 | 2014-09-12 | Biopharmed | Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas |
| CN102727489A (zh) * | 2012-07-18 | 2012-10-17 | 西南大学 | 5-芳(杂环)亚甲基噻唑烷-2，4-二酮在制备ppar激动剂中的应用 |
| US20170305894A1 (en) * | 2014-10-08 | 2017-10-26 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| CN108349904B (zh) * | 2015-10-07 | 2021-08-31 | 米托布里奇公司 | Ppar激动剂、化合物、药物组合物及其使用方法 |
| WO2017180818A1 (en) | 2016-04-13 | 2017-10-19 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| SG11201901995TA (en) | 2016-10-05 | 2019-04-29 | Mitobridge Inc | Crystalline and salt forms of ppar agonist compounds |
| HRP20210294T1 (hr) | 2016-10-05 | 2021-04-16 | Mitobridge, Inc. | Postupci liječenja akutnog bubrežnog oštećenja |
-
2017
- 2017-10-05 SG SG11201901995TA patent/SG11201901995TA/en unknown
- 2017-10-05 PL PL17787774T patent/PL3523283T3/pl unknown
- 2017-10-05 DK DK17787774.3T patent/DK3523283T3/da active
- 2017-10-05 TW TW106134298A patent/TWI769182B/zh active
- 2017-10-05 AU AU2017340763A patent/AU2017340763B2/en active Active
- 2017-10-05 MY MYPI2019001560A patent/MY202008A/en unknown
- 2017-10-05 JP JP2019518286A patent/JP7017563B2/ja active Active
- 2017-10-05 UA UAA201903678A patent/UA124770C2/uk unknown
- 2017-10-05 LT LTEPPCT/US2017/055403T patent/LT3523283T/lt unknown
- 2017-10-05 HR HRP20211341TT patent/HRP20211341T1/hr unknown
- 2017-10-05 RS RS20211042A patent/RS62245B1/sr unknown
- 2017-10-05 RU RU2019110736A patent/RU2759724C2/ru active
- 2017-10-05 MX MX2019003945A patent/MX385973B/es unknown
- 2017-10-05 CN CN201780062034.5A patent/CN109843857B/zh active Active
- 2017-10-05 EP EP17787774.3A patent/EP3523283B1/en active Active
- 2017-10-05 HU HUE17787774A patent/HUE055678T2/hu unknown
- 2017-10-05 ES ES17787774T patent/ES2887008T3/es active Active
- 2017-10-05 KR KR1020197012668A patent/KR20190057129A/ko not_active Ceased
- 2017-10-05 MA MA046460A patent/MA46460A/fr unknown
- 2017-10-05 SI SI201730879T patent/SI3523283T1/sl unknown
- 2017-10-05 IL IL265730A patent/IL265730B/en unknown
- 2017-10-05 WO PCT/US2017/055403 patent/WO2018067860A1/en not_active Ceased
- 2017-10-05 PT PT177877743T patent/PT3523283T/pt unknown
- 2017-10-05 CA CA3036587A patent/CA3036587A1/en active Pending
- 2017-10-05 JO JOP/2019/0039A patent/JOP20190039B1/ar active
- 2017-10-05 US US16/334,746 patent/US10927094B2/en active Active
-
2019
- 2019-03-20 ZA ZA2019/01744A patent/ZA201901744B/en unknown
- 2019-03-29 CO CONC2019/0003162A patent/CO2019003162A2/es unknown
- 2019-04-03 PH PH12019500727A patent/PH12019500727A1/en unknown
-
2021
- 2021-02-19 US US17/179,604 patent/US11530192B2/en active Active
- 2021-08-31 CY CY20211100775T patent/CY1124655T1/el unknown
-
2022
- 2022-12-16 US US18/082,847 patent/US11912681B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3523283T (lt) | Ppar agonistų junginių kristalinės ir druskos formos | |
| LT3472157T (lt) | Kristalinės kietos bet inhibitoriaus formos | |
| PL3638666T3 (pl) | Chwastobójczo skuteczne 3-fenyloizoksazolino-5-karboksyamidy amidów kwasu tetrahydro- i dihydrofuranokarboksylowego | |
| LT3555070T (lt) | Aminu pakeisti heterocikliniai junginiai, kaip ehmt2 inhibitoriai, ir jų panaudojimo būdai | |
| IL268852A (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| LT3565542T (lt) | Polimorfinės rad1901-2hcl formos | |
| PT3548033T (pt) | Compostos e respectivos métodos de utilização | |
| LT3191461T (lt) | 6-karboksi-2-(3,5-dichlorfenil)-benzoksazolo kristalinės kietos formos | |
| LT3490988T (lt) | Naujas junginys ir gavimo būdas | |
| ES2705744R1 (es) | Accesorio de pesca para señuelos | |
| LT3519394T (lt) | Kalkobutrolio modifikacijos kristalinės formos gavimo būdas | |
| IL269626A (en) | Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2 | |
| IL284912A (en) | L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof | |
| EP3534702A4 (en) | FISHING LURES | |
| IL260004A (en) | Crystalline forms of quinolone analogs and their salts | |
| EP3560925A4 (en) | Novel compound and pharmaceutically compatible salt of it | |
| IL255625B (en) | Salts and prodrugs of 1-methyl-d-tryptophan | |
| IL313083A (en) | Terlipressin compositions and their methods of use | |
| IL280448A (en) | Crystalline epinephrine malonate salt | |
| LT3327012T (lt) | Bilastino kristalinės formos ir jų gamybos būdai | |
| LT3247711T (lt) | Naujos scy-078 druskos ir polimorfai | |
| LT3515924T (lt) | Kristalinės formos | |
| MA50937A (fr) | Nouveau composé isoxazole ou sel de celui-ci | |
| EP3469894A4 (en) | SPIDER REEL FOR FISHING | |
| HUE062106T2 (hu) | Peptid-epoxiketon-immunoproteaszóma inhibitor kristályos sói |